argenx NV ADR (ARGX)vsMesoblast Ltd (MESO)
ARGX
argenx NV ADR
$959.49
-0.28%
HEALTHCARE · Cap: $61.92B
MESO
Mesoblast Ltd
$15.12
-2.33%
HEALTHCARE · Cap: $2.01B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 4320% more annual revenue ($5.32B vs $120.25M). ARGX leads profitability with a 32.3% profit margin vs -47.8%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
MESO
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$2372.23
Current Price
$959.49
$1412.74 discount
Margin of Safety
+68.5%
Fair Value
$58.14
Current Price
$15.12
$43.02 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Revenue surging 390.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 178.3x book value
0.0% earnings growth
ROE of -18.2% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : MESO
The strongest argument for MESO centers on Revenue Growth, Debt/Equity. Revenue growth of 390.7% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : MESO
The primary concerns for MESO are EPS Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
ARGX profiles as a growth stock while MESO is a hypergrowth play — different risk/reward profiles.
MESO carries more volatility with a beta of 0.82 — expect wider price swings.
MESO is growing revenue faster at 390.7% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 26/100), backed by strong 32.3% margins and 59.3% revenue growth. MESO offers better value entry with a 68.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Mesoblast Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?